mSphere,
Journal Year:
2024,
Volume and Issue:
9(3)
Published: March 1, 2024
ABSTRACT
Pregnant
patients
are
at
greater
risk
of
hospitalization
with
severe
COVID-19
than
non-pregnant
people.
This
was
a
retrospective
observational
cohort
study
remnant
clinical
specimens
from
who
visited
acute
care
hospitals
within
the
Johns
Hopkins
Health
System
in
Baltimore,
MD–Washington
DC,
area
between
October
2020
and
May
2022.
Participants
included
confirmed
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)-infected
pregnant
people
matched
(the
matching
criteria
age,
race/ethnicity,
deprivation
index,
insurance
status,
vaccination
status
to
ensure
demographics).
The
primary
dependent
measures
were
outcomes,
infectious
virus
recovery,
viral
RNA
levels,
mucosal
anti-spike
(S)
IgG
titers
upper
tract
samples.
A
total
452
individuals
(117
335
non-pregnant)
study,
both
vaccinated
unvaccinated
represented.
increased
(odds
ratio
[OR]
=
4.2;
confidence
interval
[CI]
2.0–8.6),
intensive
unit
admittance
(OR
4.5;
CI
1.2–14.2),
being
placed
on
supplemental
oxygen
therapy
3.1;
1.3–6.9).
Individuals
infected
during
their
third
trimester
had
higher
anti-S
lower
levels
(
P
<
0.05)
those
first
or
second
trimesters.
experiencing
breakthrough
infections
due
Omicron
variant
reduced
compared
0.05).
observed
severity
antibody
responses
particularly
among
participants
suggest
that
maintaining
high
SARS-CoV-2
immunity
through
booster
vaccines
may
be
important
for
protection
this
at-risk
population.
IMPORTANCE
In
we
analyzed
samples
(SARS-CoV-2)
Hospital
Disease
severity,
including
admission,
patients.
Vaccination
recovery
patients,
but
not
nasopharyngeal
associated
responses,
especially
women
pregnancy
variants.
Taken
together,
provides
insights
into
how
COVID-19.
novelty
is
it
focuses
relationship
response
its
association
load
disease
outcomes
people,
whereas
previous
studies
have
focused
serological
immunity.
gestational
omicron
impact
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 30, 2025
The
mucosal
barrier
serves
as
a
crucial
defense
against
external
pathogens
and
allergens,
being
widely
distributed
across
the
respiratory,
gastrointestinal,
urogenital
tracts,
oral
cavity.
Its
disruption
can
lead
to
various
diseases,
including
inflammatory
bowel
disease,
asthma,
urinary
tract
infections,
inflammation.
Current
mainstream
treatments
for
mucosa-associated
diseases
primarily
involve
glucocorticoids
immunosuppressants,
but
their
long-term
use
may
cause
adverse
effects.
Therefore,
development
of
safer
more
effective
therapeutic
strategies
has
become
focus
research.
Natural
products,
with
multi-target
multi-system
regulatory
advantages,
offer
promising
avenue
treatment
diseases.
This
review
summarizes
potential
applications
natural
products
in
dysfunction
through
mechanisms
such
immune
modulation,
inflammation
inhibition,
tight
junction
protein
restoration,
gut
microbiota
regulation,
aim
providing
insights
exploration
novel
strategies.
Cell Discovery,
Journal Year:
2022,
Volume and Issue:
8(1)
Published: Oct. 21, 2022
Abstract
SARS-CoV-2
vaccine
booster
dose
can
induce
a
robust
humoral
immune
response,
however,
its
cellular
mechanisms
remain
elusive.
Here,
we
investigated
the
durability
of
antibody
responses
and
single-cell
profiles
following
immunization,
longitudinally
over
6
months,
in
recipients
homologous
BBIBP-CorV/BBIBP-CorV
or
heterologous
BBIBP-CorV/ZF2001
regimen.
The
production
neutralizing
antibodies
was
dramatically
enhanced
by
both
regimens,
could
last
at
least
six
months.
induced
faster
more
plasmablast
characterized
activation
plasma
cells
than
booster.
response
attributed
to
recall
memory
B
de
novo
cells.
Expanded
cell
clones
upon
vaccination
persist
for
their
receptors
displayed
accumulated
mutations.
positively
correlated
with
antigen
presentation
conventional
dendritic
(cDCs),
which
provides
support
maturation
through
development
follicular
helper
T
(Tfh)
proper
cDC/Tfh/B
likely
fueled
active
energy
metabolism,
glutaminolysis
might
also
play
general
role
promoting
immunity.
Our
study
unveils
booster-induced
memory/adaptive
immunity
suggests
potential
strategies
optimize
efficacy
future
iterations.
mSphere,
Journal Year:
2024,
Volume and Issue:
9(3)
Published: March 1, 2024
ABSTRACT
Pregnant
patients
are
at
greater
risk
of
hospitalization
with
severe
COVID-19
than
non-pregnant
people.
This
was
a
retrospective
observational
cohort
study
remnant
clinical
specimens
from
who
visited
acute
care
hospitals
within
the
Johns
Hopkins
Health
System
in
Baltimore,
MD–Washington
DC,
area
between
October
2020
and
May
2022.
Participants
included
confirmed
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)-infected
pregnant
people
matched
(the
matching
criteria
age,
race/ethnicity,
deprivation
index,
insurance
status,
vaccination
status
to
ensure
demographics).
The
primary
dependent
measures
were
outcomes,
infectious
virus
recovery,
viral
RNA
levels,
mucosal
anti-spike
(S)
IgG
titers
upper
tract
samples.
A
total
452
individuals
(117
335
non-pregnant)
study,
both
vaccinated
unvaccinated
represented.
increased
(odds
ratio
[OR]
=
4.2;
confidence
interval
[CI]
2.0–8.6),
intensive
unit
admittance
(OR
4.5;
CI
1.2–14.2),
being
placed
on
supplemental
oxygen
therapy
3.1;
1.3–6.9).
Individuals
infected
during
their
third
trimester
had
higher
anti-S
lower
levels
(
P
<
0.05)
those
first
or
second
trimesters.
experiencing
breakthrough
infections
due
Omicron
variant
reduced
compared
0.05).
observed
severity
antibody
responses
particularly
among
participants
suggest
that
maintaining
high
SARS-CoV-2
immunity
through
booster
vaccines
may
be
important
for
protection
this
at-risk
population.
IMPORTANCE
In
we
analyzed
samples
(SARS-CoV-2)
Hospital
Disease
severity,
including
admission,
patients.
Vaccination
recovery
patients,
but
not
nasopharyngeal
associated
responses,
especially
women
pregnancy
variants.
Taken
together,
provides
insights
into
how
COVID-19.
novelty
is
it
focuses
relationship
response
its
association
load
disease
outcomes
people,
whereas
previous
studies
have
focused
serological
immunity.
gestational
omicron
impact
